用氨苄西林和CP-45,899联合治疗由耐氨苄西林病原体引起的感染。
Treatment of infections caused by ampicillin-resistant pathogens with a combination of ampicillin and CP-45,899.
作者信息
Plouffe J F
出版信息
Antimicrob Agents Chemother. 1982 Mar;21(3):519-20. doi: 10.1128/AAC.21.3.519.
Abstract
Eleven patients infected with ampicillin-resistant organisms were treated with a combination of CP-45,899, a beta-lactamase inhibitor, and ampicillin. All infections were controlled within 7 days without any signs of toxicity.
摘要
11名感染耐氨苄青霉素微生物的患者接受了β-内酰胺酶抑制剂CP-45899与氨苄青霉素联合治疗。所有感染在7天内得到控制，且无任何毒性迹象。
相似文献
1
Treatment of infections caused by ampicillin-resistant pathogens with a combination of ampicillin and CP-45,899.用氨苄西林和CP-45,899联合治疗由耐氨苄西林病原体引起的感染。
Antimicrob Agents Chemother. 1982 Mar;21(3):519-20. doi: 10.1128/AAC.21.3.519.
2
Clinical efficacy of sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms.
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S630-3. doi: 10.1093/clinids/8.supplement_5.s630.
3
Inhibition of beta-lactamase-induced resistance in soft-tissue infections.
Arch Surg. 1985 Jan;120(1):36-42. doi: 10.1001/archsurg.1985.01390250030005.
4
Sulbactam/ampicillin versus cefoxitin in the treatment of obstetric and gynaecological infections.
Drugs. 1986;31 Suppl 2:18-21. doi: 10.2165/00003495-198600312-00005.
5
Sulbactam/ampicillin for treatment of polymicrobial pelvic infections.舒巴坦/氨苄西林用于治疗混合性盆腔感染。
Drugs. 1986;31 Suppl 2:22-5. doi: 10.2165/00003495-198600312-00006.
6
Clinical efficacy and safety of sulbactam/ampicillin in patients suffering from chronic liver disease.
J Antimicrob Chemother. 1987 Apr;19(4):527-32. doi: 10.1093/jac/19.4.527.
7
Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use.
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S644-50. doi: 10.1093/clinids/8.supplement_5.s644.
8
Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus.氨苄西林加β-内酰胺酶抑制剂（CP-45,899）治疗金黄色葡萄球菌所致实验性心内膜炎的疗效
J Infect Dis. 1981 Sep;144(3):237-43. doi: 10.1093/infdis/144.3.237.
9
10
A non-comparative study of parenteral ampicillin and sulbactam in intra-thoracic and intra-abdominal infections.
J Antimicrob Chemother. 1986 Mar;17(3):389-96. doi: 10.1093/jac/17.3.389.
引用本文的文献
1
2
Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
Drugs. 1987 Jun;33(6):577-609. doi: 10.2165/00003495-198733060-00003.
3
Pharmacokinetic and therapeutic trial of sultamicillin in acute sinusitis.舒他西林治疗急性鼻窦炎的药代动力学及治疗试验
Antimicrob Agents Chemother. 1985 Dec;28(6):832-3. doi: 10.1128/AAC.28.6.832.
4
In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.舒巴坦联合氨苄西林对厌氧菌的体外疗效
Antimicrob Agents Chemother. 1985 May;27(5):876-8. doi: 10.1128/AAC.27.5.876.
本文引用的文献
1
Interaction of clindamycin and gentamicin in vitro.克林霉素与庆大霉素的体外相互作用。
Antimicrob Agents Chemother. 1974 Nov;6(5):582-7. doi: 10.1128/AAC.6.5.582.
2
CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.CP - 45,899与青霉素或氨苄青霉素联合用于对抗耐青霉素的葡萄球菌、流感嗜血杆菌和拟杆菌。
Antimicrob Agents Chemother. 1980 Apr;17(4):615-22. doi: 10.1128/AAC.17.4.615.
3
Comparative inhibition beta-lactamases by novel beta-lactam compounds.新型β-内酰胺化合物对β-内酰胺酶的抑制作用比较
Antimicrob Agents Chemother. 1979 Feb;15(2):171-6. doi: 10.1128/AAC.15.2.171.
Zotero 插件